Literature DB >> 23494572

Oxaliplatin-induced ototoxicity in adjuvant setting for colorectal cancer: unusual side effect.

Fatima Zahra Hijri1, Samia Arifi, Naouar Ouattassi, Nawfal Mellas, Omar El Mesbahi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 23494572     DOI： 10.1007/s12029-013-9489-3

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  11 in total

1.  Oxaliplatin degradation in the presence of important biological sulphur-containing compounds and plasma ultrafiltrate.

Authors:  Elin Jerremalm; Inger Wallin; Jeffrey Yachnin; Hans Ehrsson
Journal:  Eur J Pharm Sci       Date:  2006-04-18       Impact factor: 4.384

2.  Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.

Authors:  Hans-Joachim Schmoll; Thomas Cartwright; Josep Tabernero; Marek P Nowacki; Arie Figer; Jean Maroun; Timothy Price; Robert Lim; Eric Van Cutsem; Young-Suk Park; Joseph McKendrick; Claire Topham; Gemma Soler-Gonzalez; Filipo de Braud; Mark Hill; Florin Sirzén; Daniel G Haller
Journal:  J Clin Oncol       Date:  2007-01-01       Impact factor: 44.544

3.  Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats.

Authors:  F R Luo; S D Wyrick; S G Chaney
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

4.  Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.

Authors:  Jeeyun Lee; Se Hoon Park; Heung-Moon Chang; Jun Suk Kim; Hye Jin Choi; Myung Ah Lee; Joung Soon Jang; Joung Soon Chang; Hei Cheul Jeung; Jung Hun Kang; Hyun Woo Lee; Dong Bok Shin; Hye Jin Kang; Jong-Mu Sun; Joon Oh Park; Young Suk Park; Won Ki Kang; Ho Yeong Lim
Journal:  Lancet Oncol       Date:  2011-12-20       Impact factor: 41.316

5.  First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.

Authors:  Eduardo Díaz-Rubio; Auxiliadora Gómez-España; Bartomeu Massutí; Javier Sastre; Albert Abad; Manuel Valladares; Fernando Rivera; Maria J Safont; Purificación Martínez de Prado; Manuel Gallén; Encarnación González; Eugenio Marcuello; Manuel Benavides; Carlos Fernández-Martos; Ferrán Losa; Pilar Escudero; Antonio Arrivi; Andrés Cervantes; Rosario Dueñas; Amelia López-Ladrón; Adelaida Lacasta; Marta Llanos; Jose M Tabernero; Antonio Antón; Enrique Aranda
Journal:  Oncologist       Date:  2012-01-10

6.  Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Young-Woo Kim; Han-Kwang Yang; Hyun Cheol Chung; Young-Kyu Park; Kyung Hee Lee; Keun-Wook Lee; Yong Ho Kim; Sang-Ik Noh; Jae Yong Cho; Young Jae Mok; Yeul Hong Kim; Jiafu Ji; Ta-Sen Yeh; Peter Button; Florin Sirzén; Sung Hoon Noh
Journal:  Lancet       Date:  2012-01-07       Impact factor: 79.321

Review 7.  Molecular mechanisms of resistance and toxicity associated with platinating agents.

Authors:  Cara A Rabik; M Eileen Dolan
Journal:  Cancer Treat Rev       Date:  2006-11-03       Impact factor: 12.111

8.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

Authors:  Thierry André; Corrado Boni; Lamia Mounedji-Boudiaf; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Marta Zaninelli; Philip Clingan; John Bridgewater; Isabelle Tabah-Fisch; Aimery de Gramont
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 9.  Oxaliplatin-induced hepatocellular injury and ototoxicity: a review of the literature and report of unusual side effects of a commonly used chemotherapeutic agent.

Authors:  Nicole O Vietor; Benjamin J George
Journal:  J Oncol Pharm Pract       Date:  2012-02-14       Impact factor: 1.809

10.  Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity.

Authors:  Victoria Hellberg; Inger Wallin; Sofi Eriksson; Emma Hernlund; Elin Jerremalm; Maria Berndtsson; Staffan Eksborg; Elias S J Arnér; Maria Shoshan; Hans Ehrsson; Göran Laurell
Journal:  J Natl Cancer Inst       Date:  2008-12-30       Impact factor: 13.506
View more
  1 in total

1.  lncRNA MALAT1 modulates oxaliplatin resistance of gastric cancer via sponging miR-22-3p.

Authors:  Zhenming Zhang; Ming Li; Zhitao Zhang
Journal:  Onco Targets Ther       Date:  2020-02-13       Impact factor: 4.147
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.